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The nucleocapsid protein (N) of morbilliviruses is not only a major structural protein but also the most abundant protein
made in infected cells. We overexpressed the N proteins of Rinderpest virus and Peste des petits ruminants virus in E. coli,
which assemble into nucleocapsids in the absence of viral RNA that resemble nucleocapsids made in the virus-infected cells.
Employing these assembled structures resembling subviral particles, we studied the induction of both the antibody response
and the cytotoxic T-lymphocyte (CTL) response in a murine model (BALB/c). A single dose of the purified recombinant
nucleocapsids of both viruses in the absence of an adjuvant induces a strong CTL response. The CTLs generated are antigen
specific and cross-reactive with respect to each virus and, furthermore, this CTL response is MHC class I restricted. Based
on the prediction for H-2d-restricted T-cell motifs we tested the lysis of transfected P815 (H-2d) cells expressing a nine amino
acid potential CTL epitope, by splenic T cells in vitro restimulated with bacterially expressed RPV or PPRV N proteins. We
extended our study to the bovine system both to analyze the immunogenicity of these recombinant proteins in the natural
hosts and to show that PBMC from cattle vaccinated with Rinderpest vaccine proliferate in vitro, in response to restimulation
with soluble nucleocapsid proteins. Furthermore, the murine CTL epitope functions in the bovine system as a cytotoxic T-cell
epitope. This sequence, which is conserved in the N proteins of morbilliviruses, conforms well to the predicted algorithm for
some of the most common BoLA CTL antigenic peptides. © 2001 Academic Press
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Rinderpest virus (RPV) and Peste des petits ruminants
virus (PPRV) are important members of the Morbillivirus
genus in the Paramyxoviridae family and cause acute,
febrile, and contagious viral disease in large and small
ruminants, both domestic and wild. The RNA genome of
these viruses is associated with the nucleocapsid pro-
tein N in the virion and throughout the viral replicative
cycle as a filamentous ribonucleoprotein complex with a
characteristic herringbone appearance. Although the ac-
tual nature of the host-immune response to the infection
is largely unknown, the fact that there is severe immu-
nosuppression accompanying a massive virus-specific
immune response is an intriguing paradox (Randall and
Russell, 1991; Griffin, 1995; Morrison, 1995). Surface gly-
coproteins H (hemagglutinin) and F (fusion protein) in-
duce strong protective virus-neutralizing antibodies (Ro-
mero et al., 1994a,b, 1995), while the cell-mediated
mmmune response elicited by these proteins aids in
irus clearance (Norrby, 1991). Internal proteins such as
he nucleoprotein N have been found to induce strong
ell-mediated immune responses, which aid in protec-
ive immunity and, in the case of measles virus (MV),
hese N-specific T cells constitute a major fraction of thev
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210irus-specific memory cells (Griffin, 1995; Hickman et al.,
997).
Adenovirus-5 recombinant expressing MV N protein
as used to study potential CTL epitope in mouse mod-
ls (Schadeck et al., 1999). One of the H-2d-restricted
epitopes and an antigenically related morbillivirus ca-
nine distemper virus (CDV) were found to be protective
against MV. Also, a DNA vaccine encoding the nucleo-
capsid and surface glycoproteins of wild type CDV was
found to protect its naturals hosts against distemper
(Cherpillod et al., 2000). Earlier studies with a recombi-
ant baculovirus and adenovirus recombinants express-
ng RPV H and F genes demonstrated the generation of
roliferative T-cell responses, although no CTL activity
ould be detected (Bassiri et al., 1993). A recombinant
accinia virus expressing the RPV N protein was shown
o generate protective immunity upon challenge with
ildly virulent challenge virus, although protection was
ot observed in challenge experiments with a highly
irulent strain (Ohishi et al., 1999). Studies in the rabbit
odel with a vaccinia virus recombinant expressing the
ucleoprotein of the Rinderpest virus indicate that the N
rotein administered via such routes was ineffective in
riming protective immunity and, at best, can only delay
he onset of the disease in immunized animals (Naka-
ura et al., 1998). Since morbilliviruses are cytopathiciruses, an ideal subunit vaccine should include a suit-
ble combination of B-cell epitopes eliciting strong virus-
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211IDENTIFICATION OF A CTL EPITOPE ON RPV AND PPRV N PROTEINSneutralizing antibodies, such as those present on the H
and F proteins, and CTL epitopes used in infected hosts,
predominantly from the internal proteins such as the N
protein. Soluble antigens, however, very rarely generate
CTL responses (Forquet et al., 1990; Gromme et al., 1999)
and are a major hindrance in the administration of re-
combinant proteins as vaccines. Previous studies in
other viruses showed that recombinant nucleocapsid
proteins assemble into viral nucleocapsid-like structures
and can be visualized as assembled nucleocapsids by
electron microscope (Coronel et al., 1999; Fooks et al.,
1993, 1996; Spehner et al., 1991). Such assembled nu-
cleocapsid particles were reported to elicit strong virus-
specific CTL responses (Fooks et al., 1995; Fu et al., 1991;
Lo-Man et al., 1998; Marais et al., 1999; Nakamura et al.,
1998; Rudolf et al., 1999; Sedlik et al., 1999).
We expressed the RPV N and PPRV N proteins in E.
coli and the soluble recombinant N proteins assemble
into nucleocapsid-like structures in the absence of viral
RNA (unpublished results). In the present work, we stud-
ied the immune responses to these assembled nucleo-
capsids in the BALB/c mouse model, induced by a single
low dose of immunization without any adjuvant or
booster administration. Based on structural predictions
FIG. 1. Purification of bacterially expressed RPV and PPRV N pro-
eins. The cDNA coding for the RPV and PPRV nucleocapsid proteins
ere expressed from pET20b and pRSET B respectively in the E. coli
L21(DE3). Expression from the T7 promoter was induced by 0.4 mM
PTG for 4 h, purified to near homogeneity by ultracentrifugation on a
sCl gradient, and electrophoresed on a 10% SDS–PAGE. The authen-
icity of the expressed protein and the purity was checked by transfer
nto a nitrocellulose membrane and probing the blot with anti-N anti-
ody raised against the purified viral nucleocapsids.and homology to a highly conserved immunodominant
epitope of measles virus N protein (Beauverger et al.,
w
m1993, 1996), oligonucleotide sequences corresponding to
a nine amino acid CTL epitope were designed and
cloned in a prokaryotic vector. This was moved into a
eukaryotic vector along with 59 extra sequences harbor-
ing the initiator codon, to facilitate transient expression
of the CTL epitope. Using this construct, we identified the
CTL epitope on N protein in the BALB/c mouse, which is
(H-2d) restricted. We used a similar approach to map this
sequence as a BoLA (bovine leucocyte antigen)-re-
stricted cattle CTL epitope in cattle.
RESULTS
Recombinant RPV and PPRV nucleocapsid proteins
induce proliferation of immune lymphocytes in vitro
Recombinant RPV and PPRV nucleocapsid proteins
were expressed in E. coli and purified by density gradi-
ent ultracentrifugation. Figure 1 shows the purity of the
protein ascertained by SDS–PAGE and Western blot. The
purified proteins were further subjected to electron mi-
croscopy and were seen as assembled nucleocapsids
very similar to the assembled structure of the viral nu-
cleocapsids as shown in Fig. 2. Such assembled struc-
tures were used to immunize mice and the immune
responses studied in these immune BALB/c mice. The
proliferative responses of splenocytes from immune
mice were found to be dose dependent (data not shown)
and were optimum at an antigenic dose of 2 mg/well, as
seen in Fig. 3. The incubation of the cells in the presence
of anti-murine class II antibodies was found to inhibit the
proliferation, although the inhibition was not complete.
This indicated the expansion of T cells by mechanisms
other than that of either MHC II–CD41 interactions or,
more simply, the activation of the CD81 T cells in re-
sponse to MHC presentation of endogenously pro-
cessed peptides from recombinant RPV and PPRV nu-
cleocapsid proteins.
FIG. 2. Electron microscopy of the assembled recombinant nucleo-
capsids. Purified nucleocapsid proteins expressed in E. coli BL21(DE3)
ere resuspended in PBS at a concentration of 250 mg/ml. The grid
as examined in a Jeol 100cX11 electron microscope at 80 kV at a
agnification of 100,0003.
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212 MITRA-KAUSHIK, NAYAK, AND SHAILAGeneration of MHC class I-restricted CTL activity in
immune BALB/c lymphocytes
Effector cells were prepared by the restimulation of
isolated immune lymphocytes by the recombinant N pro-
teins in vitro for 5 days and incubated with syngenic P815
targets. The specific stimulated effectors show up to 60%
specific lysis at an E:T ratio of 80:1 with homologous
targets as well as cross-reactive targets, i.e., RPV N
immune effectors cocultured with PPRV N expressing
P815 cells, depicted in Fig. 4A. Similarly PPRV N immune
effectors brought about the specific lysis of both homol-
ogous and cross-reactive targets. The percentage spe-
cific lysis in this case was up to 50% at an E:T ratio of
80:1, as shown in Fig. 4B. The MHC I restriction of the
CTL lysis was seen from inhibition of the lysis by the
anti-MHC class I antibodies in the case of both immune
effectors. The lysis by lymphocytes from control animals
was subtracted to represent antigen-specific lysis.
Epitope-specific CTL responses in mice immunized
with the recombinant N protein expressed as
assembled nucleocapsids
The predicted measles virus CTL epitope was found to
be conserved in both RPV and PPRV N proteins, and we
derived both H-2d and BoLA binding predictions (Hegde
et al., 1995, 1999; Hegde and Srikumaran, 1996) for this
sequence (Table 1). We cloned the synthetic minigene
harboring this sequence for CTL epitope in a eukaryotic
expression vector (Fig. 5) and the minigene construct
was used to transfect P815 cells which were subse-
FIG. 3. In vitro proliferation of BALB/c immune T cells in response to
ecombinant nucleocapsid proteins. Lymphocytes were prepared from
pleen of immune animals 3 weeks after immunization and further
urified through Ficoll–Hypaque. Lymphocytes (1 3 104) were plated in
96-well plates with either RPV N (3), PPRV N (u) at different concen-
trations, RPV N 1 anti-MHC II antibodies (h), PPRV N 1 anti-MHC II
(s) antibodies, or without any antigen ( ) and incubated for 5 days.
riplicate samples of cells were labeled with [3H]thymidine and the
incorporated radioactivity was measured.quently used as targets in a typical CTL assay. Figure 6
shows the results of this assay, in which the lysis of theepitope-expressing targets appears to be similar to that
of the targets expressing the full-length RPV N protein,
indicating that this epitope may be one of the immuno-
dominant epitopes in the H-2d-restricted animals. As
expected, the lysis was abrogated by preincubation of
the targets with anti-MHC class I antibodies, thus con-
firming the authenticity of this predicted nine amino acid
sequence as a CTL epitope.
FIG. 4. (a) CTL assay using RPVN immunized BALB/c lymphocytes
stimulated in vitro with recombinant RPVN or PPRV N. Lymphocytes
were isolated from immune animals 3 weeks postimmunization and
restimulated in vitro with the respective N proteins for 5 days. A CTL
assay was performed in 96-well plates using RPV-infected P815 targets
(), PPRV-infected P815 targets (n ), RPV-infected targets 1 anti-MHC I
antibodies (), RPV N stable transfected targets (F), PPRV N stable
transfected targets (}), and RPV N stable transfected targets pre-
treated with anti-MHC I antibodies (E). The percentage specific lysis
was calculated according to the manufacturer’s directions and is the
mean of triplicate wells. (b) CTL assay using PPRVN-immunized
BALB/c lymphocytes. Isolated PPRV N immune, murine splenic lym-
phocytes harvested 3 weeks postimmunization were restimulated in
vitro with E. coli expressed and purified PPRV N or RPV N and used in
a CTL assay with targets as follows: PPRV-infected P815 targets (),
RPV-infected P815 targets (n ), PPRV-infected targets 1 anti-MHC I
antibodies (), PPRV N stable transfected targets (F), RPV N stable
transfected targets (}), and PPRV N stable transfected targets pre-
treated with anti-MHC I antibodies (E).
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213IDENTIFICATION OF A CTL EPITOPE ON RPV AND PPRV N PROTEINSMHC class I-biased proliferation of PBMC from RPV-
vaccinated cattle
To study the immunological properties of the prolifer-
ating T cells as seen in this study we demarcated the
functional responders with respect to their CD41 and the
CD81 T-cell nature, especially since the response is to a
classical internal viral protein, which is normally pre-
sented to CTLs in the context of MHC I presentation.
Skin fibroblast cells were previously shown to be MHC I1
and MHC II2 and, therefore, proliferation induced by
such antigen-presenting cells is mostly the result of
antigen presentation by the MHC class I pathway (Ohishi
et al., 1999). We used a similar assay to define the T-cell
esponses to the RPV N and the PPRV N, as well as the
TL epitope, by coculturing the immune PBMC after in
vitro restimulation with the irradiated autologous skin
cells of the bull transiently expressing the full-length RPV
N or the PPRV N or the CTL epitope from the transfected
DNA constructs. The observed proliferation was plotted
in Fig. 7 and is expected to be represented in majority by
the CD81 T-cell proliferations. The stimulation index in
his assay was found to be between 5 and 6 and the
TABLE 1
Comparison of the Conserved Nine Amino Acid Sequence with the
Peptide Motif of the Cattle MHC Class I Antigen BoLA A-11
Allele 1 2 3 4 5 6 7 8 9 10 11 12
BoLA A-11a X P A I P V L Q I Y A V
1 F P G I I V V
V M A K V F L
N L Y Q Y I Y
K E m L P E
Y G q G G Y
L T h A r a
T n d E k w
G w e d r
R c s
E t
S
D
i
m
q
RPV N aa 281–289 Y P A L G L H E F
PPRV N aa 281–289 Y P A L G L H E F
Note. Positional characteristics for BoLA A-11-bound peptides were
compared. The numbers indicate the positions in the peptides eluted
from BoLA A-11 antigen, and the amino acids are represented in
single-letter codes. The descending order of amino acids approxi-
mately corresponds to the stength of the signal. Lowercase letters
indicate weak anchors; bold letters indicate dominant anchors; under-
lined letters indicate possible auxiliary anchors. The conserved nine
amino acids of the two viruses are compared for possible presentation
on BoLA antigens.
a See Hickman et al. (1997)roliferation values for the CTL epitope matched that of
he full-length RPV N or PPRV N, as was also observed in
1
athe murine model. This confirms our observation that this
nine amino acid sequence is indeed a CTL epitope for
the BoLA restriction in the single vaccinated bull that we
used in this study. Although this epitope needs to be
tested in a more significant number of cattle, our findings
suggest the definitive contribution of this epitope in the
RPV N-specific CTL response.
CTL responses to the recombinant RPV N and PPRV
N proteins in the bovine model
The N-specific CTL response was determined by the
lysis of RPV N, PPRV N, or CTL epitope expressing
autologous skin fibroblast targets. Untransfected skin
cells were used as negative controls in the CTL assays.
Effectors were generated by in vitro restimulation of the
vaccinated PBMC by RBOK-RPV- or PPRV Nigeria 75/1-
infected autologous skin cells for 5 days. We used PPRV-
infected cells as a cross-reactive PPRV antigen-present-
ing cell and, interestingly, we find good levels of specific
lysis with both of the effector populations, as shown in
Fig. 8. It is expected that the conservation of the se-
quence in these related viruses would ensure the lysis of
the PPRV targets, if there indeed were any T cells di-
rected to the conserved cross-reactive epitopes on both
proteins. The results conclusively show that the nine
amino acid BoLA CTL epitope, which is conserved in
almost all morbilliviruses, is also a dominant epitope in
the bovine system. The detection of N-specific CTL after
a secondary response in a natural host lends support to
a further characterization of this protein for candidate
epitopes in a subunit vaccine.
DISCUSSION
The most important observation in this study is that
bacterially expressed recombinant RPV and PPRV nu-
cleocapsid proteins elicit strong CD81 T-cell responses,
detectable both in BALB/c mice and in the target animal.
The work confirms the earlier observation from other
laboratories that N protein-immune CD41 and CD81 T
cells proliferate in vitro when restimulated with both
recombinant assembled nucleocapsids as well as MHC
I-bound processed peptides on transfected or infected
antigen-presenting cells (Forquet et al., 1990; Jondal et
l., 1996; Sedlik et al., 1999). The recombinant N proteins
ere found to generate high titers of antibodies that are
ot virus neutralizing, indicating the immunogenecity of
uch recombinant protein structures used as virus-like
articles. Spleens of BALB/c mice immunized with puri-
ied recombinant RPV nucleocapsid or PPRV nucleocap-
id proteins showed an increase in their dry weight at
he end of 3 weeks (data not shown), indicating high
evels of proliferation of splenic lymphocytes. The im-
une mice developed N-specific antibody titers of up to
:16,000 at 2 weeks after immunization and the levels of
ntibody were maintained until 3 weeks postimmuniza-
inigen
c
214 MITRA-KAUSHIK, NAYAK, AND SHAILAtion (p.i.) at similar levels (data not shown). The antibod-
ies were cross-reactive with respect to the two antigens
used in this study (data not shown). Although the N-
FIG. 5. Schematic representation of the generation of the synthetic m
ells.specific antibodies are not expected to be of any use in
the clearance of infected cells or of cell-free virus parti-cles, the high antibody levels indicate an ongoing re-
sponse to the immunization mediated by T-cell help.
CD41 cells generated in these responses not only play
e construct harboring the N CTL epitope for expression in eukaryotica role in the activation of virus-specific CTLs but also
help to produce virus-specific B cells in a secondary
215IDENTIFICATION OF A CTL EPITOPE ON RPV AND PPRV N PROTEINSresponse. Quite notably the N protein-specific T cells
were previously found to comprise the bulk of the virus-
specific memory cells in the paramyxovirus family (Karp
et al., 1996). Since RPV and PPRV are cytopathic viruses
such activated CD81 T cells are unlikely to be involved in
the acute stage of the disease, since here the control is
more likely to be mediated by neutralizing antibodies. At
FIG. 6. CTL lysis of target cells expressing the N CTL epitope. P815
cells were transfected with the minigene construct expressing the nine
amino acid CTL epitope and used as targets in a standard LDH release
cytolysis assay. Untransfected P815 cells were also included as neg-
ative target to determine the background or nonspecific lysis of the
assay conditions. The immune effectors obtained from RPV N and,
PPRV N immune mice splenocytes were coincubated with the following
target cells: RPV N (}), CTL construct (F), P815 cells (), and CTL
construct 1 anti-MHC I antibodies (n ) for 16 h.
FIG. 7. Class I-biased proliferation of vaccinated cattle PBMC. Au-
tologous skin fibroblasts transfected with the RPV N gene (}), PPRV N
gene ( n ), CTL epitope (), or vector-transfected cells (F) were used in
a proliferation assay against the immune bovine PBMC in a prolifera-
tion assay performed 28 weeks postimmunization at different cell
densities of the stimulator cells. Incorporation of the tritiated thymidine
by the proliferating bovine lymphocytes was measured 5 days after
restimulation.later stages, however, particularly during the establish-
ment of infection, when these CD81 T cells are known to
proliferate, it is possible that they may play an as yet
undefined role in the immunosuppression and immuno-
modulation associated with the infections (Morrison,
1995; Karp et al., 1996). Typically, CD81 cells function at
an early stage in virus invasion and recognize nonstruc-
tural proteins synthesized before the virus has been
released from the cells. The CD41 and CD81 T cells may
act either by interfering with virus replication through the
secretion of cytokines such as interferon g (IFN-g) or
more directly by specific MHC-linked cytotoxic activity
toward virus-infected cells. The functional correlation
between activation of CD81 and the determination of the
role of major and minor T-cell epitopes in the establish-
ment of effective immunity constitute areas of future
research.
To focus on the T-cell responses in mice we used
bacterially expressed nucleocapsids to immunize mice
(Jondal et al., 1996). Immune splenic lymphocytes prolif-
erate in vitro when restimulated with such assembled
structures and the proliferation was inhibited by the
addition of anti-murine MHC II antibodies. Importantly,
the proliferative responses in vitro were not only RPV
specific but also cross-reactive with PPRV, indicating that
some of the CD41 and CD81 T-cell epitopes are con-
served.
The generation of CTL–proficient in virus-infected cell
killing was demonstrated by the MHC class I-restricted
lysis of syngenic antigen-presenting cells presenting
processed N peptides derived from the transfected
cDNA or virus infection in these target cells. Once again
FIG. 8. Cytotoxic T-cell activity of PBMC from vaccinated cattle. CTL
assay in the bovine system was performed similarly to that of the MHC
I-biased CTL assay, except that the effector cells were restimulated in
vitro for 5 days with the RPV- or PPRV-infected autologous skin fibro-
blast cells before the CTL assay was set up. Subsequently, the effector
cells were harvested and plated with the targets, RPV N transfected
fibroblast (}), PPRV N transfected fibroblasts ( n ), and CTL epitope
transfected cells (), and vector DNA transfected control cells (F) at
different effector:target ratios for the CTL assays.the cross-reactivity of the N-specific lysis in immune T
cells arising from RPV N- or PPRV N-immune mice con-
tt
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216 MITRA-KAUSHIK, NAYAK, AND SHAILAfirms our earlier result, where we observe proliferation
resulting from conserved epitopes.
We then proceeded to map a dominant H-2d-restricted
CTL epitope in BALB/c mice using a DNA construct
encoding the nine amino acid conserved measles virus
epitope spanning amino acids 281–289 on RPV N and
PPRV N proteins. These constructs were used to trans-
fect syngenic cells and such epitope-expressing cells
were used as targets in a CTL assay. The MHC I-re-
stricted lysis of specific cells by both RPV N- and PPRV
N-immune lymphocytes proved that the sequence in
question was indeed an H-2d-restricted CTL epitope.
To demonstrate CD41 and CD81 T-cell responses in
the natural host, we performed a proliferation assay of in
vitro restimulated PBMC, which showed the induction of
proliferation of bovine PBMC from the RBOK-RPV-vacci-
nated animal. Lymphocytes were isolated from a vacci-
nated calf at different time points postvaccination and
tested for the ability to proliferate in response to in vitro
restimulation with RPV N proteins expressed as nucleo-
capsid-like structures. Incorporation of radioactive thy-
midine indicated that the cultures were proliferating in
response to soluble antigen, possibly in response to
processed N peptides generated by the ingestion of the
assembled nucleocapsid structures by the professional
APCs present in the pool of PBMC used in the experi-
ment (data not shown). The stimulation index was low (in
the order of 2–3) but increased to 8 after a booster was
administered to the bull at the end of 24 weeks p.i.,
indicating the generation of N-specific memory. To fur-
ther assign the proliferation observed above to the CD41
and CD81 T-cell compartments, a proliferative assay
based on antigen presentation by MHC class I1 and
MHC class II2 skin fibroblasts was employed. The use of
his assay demonstrated clearly the presence of CD81 T
cells capable of responding to the RPV N or the PPRV N
as well as the H-2d-restricted CTL epitope expressed in
transfected autologous skin cells.
The results of the class I-biased proliferation assay
were substantiated by employing a direct CTL assay. The
CTL assay demonstrated conclusively the CD81 speci-
ficity of the proliferation induced by either full-length RPV
N or PPRV N or the CTL epitope identified in this study.
We found that antigen-specific, MHC I-restricted killing of
autologous skin cells transfected with RPV N, PPRV N, or
the CTL epitope by CTLs generated in the RBOK-RPV-
vaccinated bull. We used the PPRV Nigeria 75/1 strain of
PPRV to infect the autologous skin fibroblasts and then
used these cells to restimulate in vitro the PBMC and
found cross-reactive CTLs in the case of all three targets
used, confirming the conserved use of the nine amino
acid epitope in both RPV N and PPRV N proteins.
Similar to observations made in related viruses, such
as that of the generation of CD81 T-cell responses in a
mouse model to the adenovirus recombinant of the mea-
sles virus N protein (Fooks et al., 1995) or the vacciniavirus recombinant harboring the measles virus N protein
gene (Spehner et al., 1991), this study clearly establishes
that CD81 T cells participate in the immune response to
RPV- and PPRV-infected cattle. We established a clear
role for MHC I-restricted T cells in the control of virus
spread and defined a CTL epitope on the N proteins of
RPV and PPRV N to which T cells from immune mice and
vaccinated cattle can respond. This H-2d-restricted CTL
epitope has been found to be widely conserved among
all morbillivirus N proteins and experimental evidence
has been provided to show the cross-reactivity to canine
distemper virus N protein (Beauverger et al., 1993). It will
be rewarding to study the significance of this CTL
epitope in a statistically larger set of animals. In light of
the finding that the NP-DNA immunization failed to pro-
tect the immunized mice in the influenza system, it is of
prime importance to look for alternate methods to prime
the animals against the N proteins which provide a major
target for virus-specific cell-mediated immunity (Childer-
stone et al., 1999). It will also be important to see whether
the use of such recombinant structures can elicit similar
immune responses, especially those of cytokines such
as IFN-g and use them to study more elusive mecha-
nisms associated with morbilliviruses such as immuno-
suppression and immunomodulation.
MATERIALS AND METHODS
Cells and viruses
Bovine primary skin fibroblasts were cultured from
skin biopsies of the experimental animal and were main-
tained in IMDM supplemented with 20% FBS (fetal bo-
vine serum) and human recombinant EGF (epidermal
growth factor; Boehringer Mannheim, Mannheim, Ger-
many) at a concentration of 10 ng/ml. These were frozen
in liquid nitrogen storage for further use.
P815, a H-2d murine mastocytoma cell line, was main-
ained in RPMI 1640 (Life Technologies, Gaithersburg,
D) containing 5% heat-inactivated FBS, 50 mM L-glu-
tamine, 0.1 mM b-mercaptoethanol, and 100 mg of strep-
tomycin/penicillin.
The Vero cell line (obtained from National Center for
Cell Science, India) was maintained in MEM (minimum
essential medium) containing 5% FBS and 100 mg of
strepto-penicillin.
RPV, a tissue-culture-adapted vaccine strain (RBOK,
the original attenuated Kabete “O” strain of RPV) was
obtained from the Institute of Animal Health and Veteri-
nary Biologicals (Bangalore, India). Virus stocks were
propagated by infection and recovery in Vero cells and
subsequently titrated by TCID50 assay in Vero cells as
described previously (Reed and Muench, 1938).
The vaccine strain of PPRV (Nigeria 75/1), kindly pro-
vided by Dr. A. Diallo (CIRAD-EMVT, France), was grown
in Vero cells and the titer was determined by TCID50
assay in Vero cells (Reed and Muench, 1938).
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217IDENTIFICATION OF A CTL EPITOPE ON RPV AND PPRV N PROTEINSAnimals and immunization
One male calf (Jersey breed) tested negative for RPV
or PPRV antibodies was vaccinated intramuscularly (im)
with one dose of Tissue Culture Rinderpest Vaccine
(Rinderpest vaccine strain RBOK, obtained from the In-
stitute for the Animal Health, Pirbright Laboratory, U.K.)
and boosted 6 months later) with three im doses of RPV
tissue culture vaccine (made at Institute for Animal
Health and Veterinary Biologicals, Bangalore).
BALB/c (H-2d) female mice were obtained from the
Central Animal Facility, Indian Institute of Science. Six- to
8-week-old mice were immunized with 25 mg of recom-
inant proteins in PBS subcutaneously (sc). Serum or
pleens were obtained 3 weeks postimmunization.
ntibodies
Monospecific polyclonal rabbit anti-RPV N was raised
gainst the purified bacterially expressed RPV N protein
nd concentrated by 50% ammonium sulfate saturation,
ollowed by extensive dialysis against PBS (phosphate-
uffered saline). Serum from PPR disease-convalescent
heep or goats naturally infected with PPRV was used as
source of anti-PPRV antibodies.
Antibodies used for blocking of T-cell proliferation and
TL assays were obtained as a gift from Dr. D. Nandi
Dept. of Biochemistry, Indian Institute of Science).
onoclonal antibodies in the form of ascites fluid rec-
gnizing the H-2d determinant (HB79, ATCC, Manassas,
VA) and recognizing the MHC class II, I-A, and I-E deter-
minants (TIB120, ATCC) were used at a dilution of 1:200
in the assays.
Construction of recombinant plasmids
The full-length N genes of RPV (RBOK vaccine) and
PPRV (Nig 75/1 vaccine) were earlier subcloned, ex-
pressed, and characterized (unpublished results). The
RPV N gene in pET20b, pSDN2 (Daniel and Shaila, 1999),
and PPRV N clone in pRSET B (PGKN1) were used to
transform E. coli BL21 (DE3) for large-scale expression.
The full-length RPV-RBOK N gene cDNA (Baron and
Barrett, 1995) and the PPRV-Nig 75/1 N gene cDNA
(Diallo et al., 1994) were subcloned in the pCMX PL1
eukaryotic vector at the NotI site and BamHI–XhoI sites,
respectively. Expressions from these constructs, pCXRN
and pCXPN, respectively, were assayed by immunofluo-
rescent staining of transfected cells. The transfection
was performed as described for the generation of stable
transfectants described below.
The full-length RPV-RBOK N gene cDNA and the PPRV-
Nig 75/1 N gene cDNA were subcloned in the pCDNA3
eukaryotic vector (Invitrogen, San Diego, CA) in the mul-
tiple cloning site at the NotI and the EcoRI–NotI sites,
respectively, for stable expression in eukaryotic cells.
The pCDNA3 series of vectors have a neomycin-resis-tance cassette in addition to the genetic elements re-
quired for propagation in both prokaryotic and eukaryotic
hosts.
The full-length pCDNA3 constructs pSRN6neo and
pSPN6neo were used to transform E. coli DH5a for isola-
tion of plasmid DNA for stable transfection.
Synthetic oligonucleotides were designed and synthe-
sized (Bangalore Genei, India) as minigenes (Schirm-
beck et al., 1995) encoding nine amino acids of a pre-
dicted CTL epitope YPALGLHEF (Beauverger et al., 1993,
996), which corresponds to amino acids 281–289 on
oth RPV N and PPRV N proteins and were flanked by
oncomplementary restriction sites BamHI and PstI rep-
esented as underlined bases: {oligo N1 59-ACG-
GATCCCTACCCAGCACTGGGCCTGCATGAATTCACT-
GCAGCCAA-39; oligo N2 59-TTGGCTGCAGTGAATTC-
ATGCAGGCCCAGTGCTGGGTAGGGATCCGGTT-39}. The
oligonucleotides were annealed, digested with the re-
striction enzymes to generate sticky ends, and ligated
directionally into pRSET B. The recombinant clones were
confirmed by colony hybridization with the radiolabeled
N1 oligonucleotide. A positive clone was then used to
release the minigene along with the vector transcription
start site and stop signal. This released fragment was
further ligated directionally into the eukaryotic expres-
sion vector pCMX.PL2 containing CMV immediate-early
gene promoter, f1 origin of replication, SV40 origin of
replication and promoter, and a multiple cloning site.
Recombinant clones were confirmed by colony hybrid-
ization with N1 oligo probe, and a single positive colony
was selected (pSM2) and used to prepare DNA for all
transfection experiments. The schematic representation
of the generation of the synthetic CTL epitope construct
is shown in Fig. 5. DNA for all transfections were pre-
pared in prepacked columns Qia-tip 100 (Qiagen, Chats-
worth, CA) according to the manufacturer’s instructions.
Generation of stable transfectants
P815 cells were seeded on 60-mm tissue culture pet-
riplates and transfected with 5–10 mg each of the
pSRN6neo or pSPN6neo constructs in OPTIMEM (Life Tech-
nologies) using lipofectamine for 12 h. After 12 h the
transfection medium was removed and replaced by nor-
mal RPMI 1640 containing 5% FBS for 72 h. G418 (gene-
ticin) was added to these cultures at a concentration of
400 mg/ml and the resistant cells were screened for
expression of the RPV and PPRV N proteins 3 weeks
after antibiotic selection was applied. The clones were
selected by single-cell cloning in the presence of the
antibiotic by the limiting dilution method. The expression
from these cells was assayed by immunofluorescent
staining of stably transfected clones. The positive clones
were maintained in 100 mg/ml of G418 (Life Technolo-
gies).
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E. coli BL21(DE3) cells transformed with pSDN2 (RPV
) or pGKN1 (PPRV N) were grown in 500 ml LB medium
nd induced with 0.4 mM IPTG for 5 h. Harvested cells
ere resuspended in Buffer A containing 50 mM Tris–
Cl, pH 8, 7.5% glycerol, 0.1 mM EDTA, 1 mM DTT, and 50
M NaCl. The cells were then lysed on ice for 1 h by the
addition of Buffer B containing 50 mM EDTA, 10% Triton
X-100, and 2.5 mg/ml lysozyme. The cells were sonicated
briefly after the addition of 5 mM MgCl2 and the lysate
was clarified by a high-speed spin at 13,000 rpm for 30
min at 4°C. The nucleocapsids were purified as de-
scribed earlier (Daniel and Shaila, 1999). Briefly, 1–2 ml of
the cleared lysates were layered over a 20, 30, and 40%
(w/v) step CsCl gradient prepared in PBS and centrifuged
in a SW41 rotor at 37,000 rpm in a Beckman ultracentri-
fuge (Beckman Coulter, Fullerton, CA) for 16 h at 4°C.
The NC band at the interface of the 30 and 40% layers
was collected and diluted in 10 volumes of PBS and
further pelleted in a Ti-70 Beckman rotor at 43,000 rpm
for 1 h at 4°C. The pellet obtained was resuspended in
400 ml of PBS. The protein content was estimated by
Bradford’s method and the purity was checked by
Coomassie staining of samples run on SDS–PAGE.
Electron microscopy
Purified nucleocapsid proteins were resuspended in
PBS at a concentration of 250 mg/ml. The NC particles
were visualized by placing the sample over a copper grid
coated with carbon film and allowed to adsorb for 2 min.
The grid was subsequently washed with distilled water
for 30 s and negatively stained with 2% potassium phos-
photungstate, pH 7.0, for 1 min. The grid was air-dried at
room temperature for 10–15 min and examined in a Jeol
100cX11 electron microscope at 80 kV.
Lymphocyte proliferation assays with soluble
antigens
Lymphocytes were prepared from the immune spleen
and purified on a Ficoll–Hypaque (Pharmacia, Piscat-
away, NJ) gradient by centrifugation at 3000 rpm for 30
min. The buffy coat layer was recovered, washed with
RPMI, and resuspended in RPMI containing 10% FBS. A
total of 1 3 104 splenic lymphocytes were plated per well
and incubated with different concentrations of the solu-
ble RPV or PPRV N proteins in a final volume of 200
ml/well for 5 days. Tritiated thymidine (0.5 mCi/well; spec.
act. 6500 mCi/mmol; BARC, Mumbai, India) was added
16 h before harvesting the cultures. The incorporated
radioactivity was measured in a scintillation spectrome-
ter.
CTL assays in the murine systemThree weeks after the immunization with purified nu-
cleocapsids, splenic lymphocytes were harvested as de-scribed above and restimulated in vitro with 2 mg of
purified RPV or PPRV nucleocapsids. After 5 days CTL
activity was assessed using P815 cells infected with
RBOK RPV or PPRV Nig 75/1 or P815 cells transfected
with pCXRN or pCXPN or stably transfected P815 cells
(described above) or CTL epitope-expressing cells
(pSM2 transfected) as target cells. CTL activity was mea-
sured by a CTL detection kit (Boehringer Mannheim) as
described in the manufacturer’s instructions. The per-
centage specific lysis was calculated by the formula
% specific lysis
5 100 3
~experimental 2 spontaneous release!
~total release 2 spontaneous release!
ovine MHC class I-biased lymphocyte proliferation
ssays
Autologous primary skin fibroblast cells obtained from
he experimental animal before vaccination (see above)
ere transfected with 10 mg of the plasmid constructs
containing the full-length RPV N (pCXRN) or PPRV N
(pCXPN) or the pSM2 DNA and 24 h after transfection
cells were gamma-irradiated at 3500 rads for 3 min
before use as CTL targets. Target cells were plated in a
96-well flat-bottom tissue culture plate (Nalge Nunc,
Rochester, NY) in different numbers ranging from 2000 to
8000 cells/well. Bovine PBMC were isolated from 1:2-
diluted heparinized blood and purified on Ficoll–
Hypaque as above. The buffy coat was recovered,
washed with RPMI, and resuspended in RPMI containing
10% FBS. PBMC (1 3 105) were added to the irradiated
stimulators in a final volume of 200 ml and incubated in
a humidified CO2 incubator at 37°C for 5 days. Control
assays were set up using untransfected fibroblasts as
stimulators. Tritiated thymidine (0.5 mCi/well) was added
16 h before harvesting the cultures. The incorporated
radioactivity was measured in a scintillation spectrome-
ter. The stimulation index (SI) was calculated by:
SI 5
mean cpm of triplicate antigen-stimulated wells
mean cpm of triplicate control wells
Bovine cytotoxic T-lymphocyte (CTL) assays
Autologous primary skin fibroblast cells (1 3 106) were
transfected with 10 mg of the pCXRN, pCXPN, or the
pSM2 plasmid DNA using lipofectamine (Life Technolo-
gies) for 24 h. Cells were gamma-irradiated at 3500 rads
for 3 min. Cells were plated in a 96-well flat-bottom tissue
culture plate (Nalge Nunc). PBMC isolated as described
earlier were added at differentratios to these targets in a
final volume of 200 ml and incubated in a humidified CO2
incubator at 37°C for 12 h. Control assays were set up
using uninfected fibroblasts as targets. The presence of
CTL activity was assessed in triplicate experiments.
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